Earnings History Data for Larimar Therapeutics (LRMR) - NYSE NASDAQ
To lookup another company type a stock symbol and press 'Go'. The overview will show the earnings release info that is available in TheStockCatalyst database for the company.
For historic stock the Extended Hours price data shown are from just before market open on the day of release for premarket earnings releases and of the day after release for afterhours earnings releases. The normal price data is from just before market close on the days of release for premarket releases and the day after release for afterhours releases.
For historic stock the Extended Hours price data shown are from just before market open on the day of release for premarket earnings releases and of the day after release for afterhours earnings releases. The normal price data is from just before market close on the days of release for premarket releases and the day after release for afterhours releases.
See the full list of available companies here.
Larimar Therapeutics
Larimar Therapeutics Inc. is a clinical-stage biotechnology company. It is focused on developing treatments for rare diseases. The company's lead product consist CTI-1601, which is in clinical stage. Larimar Therapeutics Inc., formerly known as Zafgen Inc., is based in BALA CYNWYD, Pa.
| Release Date | Time | Est. Time | Symbol | Name | Market Cap (M) | Rep. EPS | Est. EPS | Last years EPS | SeekingAlpha Headline | Price | Change | Ext. Hours Price | Ext. Hours Change | 52 Week Range | Volume | Avg. Volume | Ext. Hours Volume | Top Mover |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 30-10-2024 | PM | LRMR | Larimar Therapeutics | 511.00 | -0.24 | -0.37 | 0.00 | Larimar Therapeutics GAAP EPS of -$0.24 beats by $0.14 [10/30/2024 7:50 AM] |
8.43 | 0.65 (8.35%) |
8.00 | 0.22 (2.83%) |
2.18 - 13.68 | 715,566 | 650,000 | 4,330 | ||
| 07-08-2024 | PM | LRMR | Larimar Therapeutics | 473.00 | -0.34 | -0.32 | 0.00 | Larimar Therapeutics GAAP EPS of -$0.34 [8/7/2024 9:19 AM] |
7.16 | -0.49 (-6.41%) |
7.57 | -0.08 (-1.05%) |
2.18 - 13.68 | 363,298 | 350,000 | 627 | ||
| 09-05-2024 | PM | LRMR | Larimar Therapeutics | 519.00 | -0.27 | -0.24 | 0.00 | Larimar Therapeutics GAAP EPS of -$0.27 misses by $0.04 [5/9/2024 7:56 AM] |
7.85 | -0.07 (-0.88%) |
0.0 | 0.0 (0.00%) |
2.18 - 13.68 | 134,051 | 260,000 | 0 | ||
| 14-03-2024 | AH | LRMR | Larimar Therapeutics | 385.00 | -0.30 | -0.25 | 0.00 | Larimar Therapeutics GAAP EPS of -$0.30 misses by $0.06 [3/14/2024 5:09 PM] |
8.71 | 0.02 (0.17%) |
8.23 | -0.46 (-5.35%) |
2.18 - 13.68 | 327,794 | 570,000 | 1,004 | ||
| 14-11-2023 | PM | LRMR | Larimar Therapeutics | 106.00 | -0.21 | -0.23 | 0.00 | Larimar Therapeutics GAAP EPS of -$0.21 beats by $0.02 [11/14/2023 7:29 AM] |
2.52 | 0.13 (5.44%) |
0.0 | 0.0 (0.00%) |
2.18 - 6.85 | 146,434 | 80,000 | 0 | ||
| 15-05-2023 | PM | LRMR | Larimar Therapeutics | 228.00 | -0.15 | -0.25 | 0.00 | Larimar Therapeutics GAAP EPS of -$0.15 beats by $0.10 [5/15/2023 8:16 AM] |
3.60 | -1.45 (-28.75%) |
4.01 | -1.05 (-20.75%) |
1.53 - 6.85 | 1,572,177 | 110,000 | 423,218 | ||
| 14-03-2023 | PM | LRMR | Larimar Therapeutics | 98.00 | -0.21 | -0.78 | 0.00 | Larimar Therapeutics GAAP EPS of -$0.21 beats by $0.20 [3/14/2023 7:49 AM] |
5.91 | 0.17 (3.05%) |
5.96 | 0.23 (4.01%) |
1.53 - 6.85 | 160,061 | 280,000 | 636 | ||
| 10-11-2022 | PM | Before the open (Nov 10) |
LRMR | Larimar Therapeutics | 50.00 | -0.37 | -0.50 | 0.00 | Larimar Therapeutics GAAP EPS of -$0.37 beats by $0.12 [11/10/2022 8:48 AM] |
3.13 | 0.17 (5.78%) |
0.0 | 0.0 (0.00%) |
1.53 - 13.57 | 27,515 | 90,000 | 0 | |
| 12-05-2022 | PM | LRMR | Larimar Therapeutics | 52.00 | -0.49 | -0.62 | 0.00 | Larimar Therapeutics GAAP EPS of -$0.49 [5/12/2022 8:22 AM] |
2.56 | -0.22 (-7.91%) |
2.78 | 0.0 (0.00%) |
2.46 - 15.49 | 53,534 | 70,000 | 7,073 | ||
| 25-03-2022 | PM | LRMR | Larimar Therapeutics, Inc. | 73.85 | -0.50 | 0.00 | -0.89 | Larimar Therapeutics GAAP EPS of -$0.50 beats by $0.22 [3/25/2022 7:26 AM] |
3.99 | 0.02 (0.46%) |
0.0 | 0.0 (0.00%) |
2.71 - 17.37 | 37,537 | 225,640 | 0 | ||
| 12-11-2021 | PM | LRMR | Larimar Therapeutics | 231.00 | -0.92 | -0.62 | 0.00 | Larimar Therapeutics EPS misses by $0.25 [11/12/2021 7:48 AM] |
11.46 | -1.04 (-8.32%) |
12.50 | 0.0 (0.00%) |
7.00 - 25.87 | 59,570 | 20,000 | 156 | ||
| 12-08-2021 | PM | LRMR | Larimar Therapeutics, Inc. | 160.00 | -0.79 | -0.73 | 0.00 | Larimar Therapeutics EPS misses by $0.04 [8/12/2021 7:47 AM] |
12.98 | 1.96 (17.79%) |
0.0 | 0.0 (0.00%) |
7.00 - 25.87 | 373,997 | 110,000 | 0 | ||
| 10-05-2021 | AH | After the close (May 10) |
LRMR | Larimar Therapeutics, Inc. | 210.00 | -0.76 | -0.93 | 0.00 | Larimar Therapeutics EPS beats by $0.10 [5/10/2021 4:39 PM] |
8.42 | -4.70 (-35.82%) |
11.00 | -2.12 (-16.16%) |
8.42 - 25.87 | 513,392 | 30,000 | 94,483 | |
|
||||||||||||||||||
| 04-03-2021 | PM | LRMR | Larimar Therapeutics, Inc. | 262.13 | -0.89 | -0.72 | -1.80 | Larimar Therapeutics reports Q4 results [3/4/2021 7:31 AM] |
16.94 | -0.31 (-1.80%) |
17.00 | -0.25 (-1.45%) |
7.43 - 25.87 | 95,249 | 65,105 | 2,200 | ||
| 10-11-2020 | PM | LRMR | Larimar Therapeutics, Inc. | 303.75 | -0.64 | 0.00 | -2.88 | Larimar Therapeutics reports Q3 results [11/10/2020 8:09 AM] |
20.40 | 0.79 (4.03%) |
0.0 | 0.0 (0.00%) |
7.43 - 22.45 | 7,879 | 47,291 | 0 | ||
|
|
||||||||||||||||||